What's Happening?
Travere Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for FILSPARI (sparsentan), a medication designed to reduce proteinuria in patients aged 8 years and older with focal segmental glomerulosclerosis
(FSGS) without nephrotic syndrome. This approval marks FILSPARI as the first and only FDA-approved treatment for FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney disease. The approval is based on the results of the Phase 3 DUPLEX Study, which demonstrated significant reductions in proteinuria among patients treated with FILSPARI compared to those receiving irbesartan. The study highlighted FILSPARI's dual mechanism of action targeting endothelin A and angiotensin II receptors, which are believed to protect the kidney and reduce damage.
Why It's Important?
The FDA's approval of FILSPARI is a significant development for patients with FSGS, a rare and severe kidney disorder that often leads to kidney failure. Prior to this approval, treatment options for FSGS were limited, often relying on off-label therapies such as long-term steroids, which can have significant side effects. FILSPARI offers a new, targeted treatment option that aligns with KDIGO guidelines for managing glomerular diseases by reducing proteinuria, a key strategy in slowing disease progression. This approval not only provides a new therapeutic option for over 30,000 individuals in the U.S. with FSGS but also underscores Travere Therapeutics' leadership in addressing rare kidney diseases.
What's Next?
Following the FDA approval, Travere Therapeutics plans to make FILSPARI available for immediate prescription by nephrologists. The company will also host a conference call to discuss the approval and its implications. Travere offers a comprehensive patient support program, Travere TotalCare, to assist patients and healthcare providers with understanding FSGS, managing prescriptions, and navigating insurance processes. The approval is expected to influence treatment protocols and could lead to further research and development in the field of rare kidney diseases.
